|
Match
|
Document |
Document Title |
|
|
7390886 |
PRO9822 antibodies
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7390490 |
Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
There are provided uses of an antibody directed to CX3CR1 and fractalkine. Killer lymphocytes can be readily identified, eliminated and separated by using an anti-CX3CR1 antibody. Further, there...
|
|
|
7388080 |
Selective inhibition of toll-like receptor-2
It has been found that Toll-like receptor 1 and Toll-like receptor 2 (TLR2) physically interact. Antibodies that specifically bind to TLR2 and selectively inhibit induction of cytokines are also...
|
|
|
7388079 |
Delivery of pharmaceutical agents via the human insulin receptor
A humanized murine antibody is provided that binds to the human insulin receptor (HIR). The humanized murine antibody is suitable for use as a Trojan horse to deliver pharmaceutical agents to human...
|
|
|
7387895 |
Monoclonal antibody specific for PPAR gamma, hydridoma cell line producing the same, and method for detecting regulator related to diseases, including inflammation, cancer and metabolic diseases, using the same
The present invention relates to a hybridoma cell line producing a PPAR gamma-specific monoclonal antibody, and a method for detecting a PPAR gamma ligand related to the progression of difficult...
|
|
|
7381412 |
Anti-TECK antibodies and methods of use therefor
The invention relates to antibodies or antigen-binding fragments thereof which binds the chemokine mammalian TECK and inhibit binding of the chemokine to mammalian GPR-9-6. The invention also...
|
|
|
7378504 |
Human monoclonal antibodies to Fc gamma receptor I (CD64)
The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to CD64 with high affinity. Nucleic acid molecules encoding the antibodies of the invention,...
|
|
|
7378503 |
Antibodies against insulin-like growth factor 1 receptor and uses thereof
Antibodies which bind to IGF-IR and inhibit the binding of IGF-I and IGF-II to IGF-IR are characterized. These antibodies are implicated in anti-tumor therapy.
|
|
|
7378501 |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7378094 |
Therapeutic uses of complement receptor 2
The present invention is directed to an immune complex composition, and a method of using that complex to enhance an in viva immune response against a preselected target antigen. The immune...
|
|
|
7375196 |
PRO19814 antibodies
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7375195 |
Anti-PRO7171 polypeptides
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7374765 |
Methods and compositions for diagnosis and treatment of iron misregulation diseases
Methods and compositions are provided for the diagnosis and treatment of iron misregulation diseases, including HFE polypeptides, agonists, and antagonists, and transferrin receptor agonists and...
|
|
|
7371574 |
Antibody antagonists of VE-cadherin without adverse effects on vascular permeability
The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VIE-cadherin....
|
|
|
7371382 |
Methods of inhibiting αvβ3-mediated binding with αvβ3-specific antibodies
The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to α V β 3 , or a functional fragment thereof. The invention also provides nucleic acid molecules...
|
|
|
7371381 |
Anti-galanin antibodies and uses thereof
The present invention provides antibodies that immunospecifically bind to a galanin peptide and compositions comprising said antibodies. The present invention also provides methods for preventing,...
|
|
|
7371378 |
Modified human IGF-IR antibodies
The present invention relates to antibodies, which are directed to the human IGF-1 receptor (IGF-1R) and are to be administered for the treatment of cancer. The antibodies of the present invention...
|
|
|
7365168 |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues...
|
|
|
7361345 |
Anti-CD40 antibodies capable of blocking B-cell activation
Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen...
|
|
|
7361344 |
Co-administration of a thrombolytic and an-anti-CD18 antibody in stroke
A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective...
|
|
|
7361341 |
Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the treatment of cancers and other...
|
|
|
7358054 |
Antibodies to VLA-1
Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by...
|
|
|
7357927 |
Death domain containing receptors
The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated...
|
|
|
7355007 |
Antibodies that bind PRO5005 Polypeptides
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7354762 |
Method for producing CE7-specific redirected immune cells
Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular...
|
|
|
7354586 |
Methods of treating arthritis and diabetic retinopathy with αvβ3-specific antibodies
The present invention describes methods for inhibition angiogenesis in tissues using vitronectin α v β 3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in...
|
|
|
7351803 |
CD16A binding proteins and use for the treatment of immune disorders
CD16A binding proteins useful for the reduction of a deleterious immune response are described. In one aspect, humanized anti-CD16A antibodies, optionally lacking effector function, are used for...
|
|
|
7348001 |
Tie1-binding ligands
Tie1 is a receptor tyrosine kinase protein that includes a transmembrane domain. Tie1 is present on endothelial cells. This disclosure described antibodies that bind to Tie1, including ones that...
|
|
|
7342103 |
DIRS1 antibodies
The present invention provides nucleic acids encoding mammalian, e.g., primate or rodent receptors, purified receptor proteins and fragments thereof, and antibodies against these receptor proteins....
|
|
|
7338660 |
Methods of treating cancer and enhancing immune responses with antibodies that bind CD40
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also...
|
|
|
7332580 |
Bispecific single chain Fv antibody molecules and methods of use thereof
Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.
|
|
|
7332579 |
Antibodies to human ErbB4
The present invention concerns isolated antibodies that specifically bind to the human ErbB4 of SEQ ID NO:2, as well as humanized antibodies, human antibodies and antibody fragments, as well as...
|
|
|
7332162 |
Cell lines, ligands and antibody fragments for use in pharmaceutical compositions for preventing and treating haemostasis disorders
A ligand derived from, e.g. a Fab fragment of, a monoclonal antibody obtainable from the cell line deposited with the Belgian Coordinated Collections of Micro-organisms under accession number LMBP...
|
|
|
7329745 |
Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
A method of inhibiting the growth of hormone dependent tumor cells in a mammal comprises administering to said mammal an insulin-like growth factor receptor (IGF-IR) recombinant antibody, wherein...
|
|
|
7329406 |
Methods of treating psoriasis with αvβ3-specific antibodies
The present invention describes methods for inhibition angiogenesis in tissues using vitronectin α v β 3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in...
|
|
|
7323170 |
Anti-CD80 antibodies
The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from...
|
|
|
7321026 |
Framework-patched immunoglobulins
Framework (FR)-patching is a novel approach to modify immunoglobulin for reducing potential immunogenicity without significant alterations in specificity and affinity. Unlike previous described...
|
|
|
7320873 |
Use of antibodies against specific MHC-peptide complexes
The invention describes a method to diagnose the autoimmune disease activity by detecting the presence of an autoimmune specific MHC-peptide complex in a patient suffering from an autoimmune...
|
|
|
7319140 |
Binding compounds to DAP12 proteins
The purification and isolation of various genes which encode mammalian cell surface polypeptides. Nucleic acids, proteins, antibodies, and other reagents useful in modulating development of cells,...
|
|
|
7314912 |
AAv scleroprotein, production and use thereof
The invention relates to a structural protein of adeno-associated virus (AAV) which comprises at least one mutation which brings about an increase in the infectivity of the virus.
|
|
|
7314619 |
Inducing apoptosis using anti-Apo-2 antibodies
Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also...
|
|
|
7312320 |
Neutralizing antibodies and methods of use thereof
This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not...
|
|
|
7311910 |
Methods for treating cancer and infectious disease by blocking CTLA4-B7 interactions
The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing...
|
|
|
7309489 |
Mouse CD40 ligand-specific antibodies and hybridomas
There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human...
|
|
|
7307146 |
DNAXCCR10
Novel chemokines and 7 transmembrane receptors from mammals, reagents related thereto, including purified proteins, specific antibodies, and nucleic acids encoding the chemokines and receptors are...
|
|
|
7306800 |
Treatment of autoimmune disorders with antibodies to costimulating polypeptide of T cells
A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the monoclonal...
|
|
|
7291714 |
Glycoprotein VI and uses thereof
The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein VI, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The...
|
|
|
7291475 |
Methods of expressing integrin β6 subunits
The present invention provides substantially pure integrins containing a novel β subunit designated as β 6 . The novel β 6 subunit forms heterodimers with α v and α f . Methods of...
|
|
|
7288638 |
Fully human antibodies against human 4-1BB
Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody....
|
|
|
7288252 |
Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies
Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment...
|